World Bank Contributes Millions To New Indian Anti-Malaria Effort
This article was originally published in PharmAsia News
The World Bank has earmarked $520.8 million to help India combat several fatal diseases, particularly malaria. The program is the body's largest such project and includes funds for treating more than 100 million Indians who, on average get malaria at the rate of more than 2 million a year. The funds also are to cover prevention services. The bank noted that falciparum malaria, an often-fatal severe form, has been on the rise in the country because of increased resistance to chloroquine, the primary malaria drug. The funds are intended to provide access to a new highly effective drug regimen for malaria. (Click here for more
You may also be interested in...
Teligent has followed through with plans to condense its outstanding shares to raise their value and maintain a stock-exchange listing. Meanwhile, the company revealed a sizeable loss for the first quarter of this year, as it gave the latest on its warning letter-stricken facility in Buena, New Jersey.
Celltrion's Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the World Health Organization.
Fresenius Kabi’s Idacio biosimilar adalimumab rival to Humira will from the start of June be marketed in Germany by Medac, following a deal between the two companies.